| Identification | Back Directory | [Name]
Wnt Agonist | [CAS]
853220-52-7 | [Synonyms]
BML
-284
AMBMP
BML-284
CS-2376
Wnt Agonist
2-Amino-4-[3
Wnt Agonist I
Wnt agonist 1
BML-284 (BML 284
Wnt agonist 1 (BML-284)
BML-284 (Wnt agonist 1)
CID 11210285 hydrochloride
Wnt agonist 1 hydrochloride
CID 11210285 HCL（BML-284 HCl）
Wnt Agonist - CAS 853220-52-7 - Calbiochem
Wnt Agonist I in DMSO - CAS 853220-52-7 - Calbiochem
4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl)pyrimidine
N4-(1,3-Benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-2,4-pyrimidinediamine
2,4-Pyrimidinediamine, N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-
BML-284;2-AMINO-4-[3;4-(METHYLENEDIOXY)BENZYLAMINO]-6-(3-METHOXYPHENYL)PYRIMIDINE
2-Amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine hydrochloride
N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-2,4-pyrimidinediamine hydrochloride | [Molecular Formula]
C19H18N4O3 | [MDL Number]
MFCD09908087 | [MOL File]
853220-52-7.mol | [Molecular Weight]
350.37 |
| Chemical Properties | Back Directory | [Boiling point ]
623.4±65.0 °C(Predicted) | [density ]
1.353±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
Yellowish sticky solid | [pka]
6.62±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
CID 11210285 hydrochloride has been used as a Wnt agonist. | [Definition]
ChEBI: N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine is a member of pyrimidines. | [Biological Activity]
wnt agonist 1 is a small-molecule agonist of wnt signaling pathway [1].the wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation [1].wnt agonist 1 is a cell-permeable wnt signaling pathway agonist. wnt agonist 1 induced b-catenin- and tcf-dependent transcriptional activity in a dose-dependent way with ec50 of 0.7 μm. in xenopus embryos, treatment with wnt agonist 1 (10 μm) from developmental stage 10.5 to stage 40 resulted in substantial head defects, such as diminished heads and complete loss of eyes, and reduced eyes and heads. this phenotype is similar to that which results from wnt over-expression in head specification during early embryonic development. | [Biochem/physiol Actions]
CID 11210285 is a cell-permeable, potent and selective activator of Wnt signaling without inhibiting GSK-3β. CID 11210285is a Wnt agonist. | [References]
liu j, wu x, mitchell b, et al. a small-molecule agonist of the wnt signaling pathway. angew chem int ed engl. 2005 mar 18;44(13):1987-90. |
|
|